KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Leases (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Current Leases data on record, last reported at $2.8 million in Q3 2025.

  • For Q3 2025, Current Leases fell 70.87% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $2.8 million, down 70.87%, while the annual FY2024 figure was $3.2 million, 13.66% up from the prior year.
  • Current Leases reached $2.8 million in Q3 2025 per AMRX's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $9.7 million in Q3 2024 and bottomed at $2.2 million in Q2 2021.
  • Average Current Leases over 5 years is $4.0 million, with a median of $3.1 million recorded in 2021.
  • Peak YoY movement for Current Leases: crashed 75.09% in 2021, then soared 223.16% in 2024.
  • A 5-year view of Current Leases shows it stood at $3.1 million in 2021, then surged by 168.33% to $8.3 million in 2022, then plummeted by 66.05% to $2.8 million in 2023, then rose by 13.66% to $3.2 million in 2024, then fell by 11.99% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $2.8 million in Q3 2025, $3.3 million in Q2 2025, and $3.4 million in Q1 2025.